Lorianne K. Masuoka
Chief Tech/Sci/R&D Officer chez DIAMEDICA THERAPEUTICS INC.
Fortune : - $ au 31/03/2024
Profil
Lorianne K.
Masuoka is currently the Chief Medical Officer at DiaMedica Therapeutics, Inc. She previously held positions as the Oncology Director at Chiron Corp.
from 2000 to 2003, and as the Senior Associate Director-Clinical Development at Bayer Schering Pharma AG from 1994 to 2000.
She also served as an Independent Director at Opiant Pharmaceuticals, Inc. from 2021 to 2023, and at Pelican Inc from 2019 to 2020.
Additionally, she held the role of Chief Medical Officer & Senior Vice President at Nektar Therapeutics from 2008 to 2011, and as the Chief Medical Officer at Cubist Pharmaceuticals LLC from 2013 to 2015.
She was also the Chief Medical Officer at Marinus Pharmaceuticals, Inc. from 2017 to 2019, and the Vice President-Clinical Development at Five Prime Therapeutics, Inc. from 2003 to 2008.
Furthermore, she served as the Chief Medical Officer at Invivo Therapeutics Holdings Corp.
from 2015 to 2017.
Dr. Masuoka obtained her undergraduate and doctorate degrees from the University of California, Davis.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 22/01/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Lorianne K. Masuoka
| Sociétés | Poste | Début |
|---|---|---|
| DIAMEDICA THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 22/01/2024 |
Anciens postes connus de Lorianne K. Masuoka
| Sociétés | Poste | Fin |
|---|---|---|
| OPIANT PHARMACEUTICALS, INC. | Director/Board Member | 02/03/2023 |
| PFENEX INC. | Director/Board Member | 01/10/2020 |
| MARINUS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 31/10/2019 |
| INVIVO THERAPEUTICS HOLDINGS CORP. | Chief Tech/Sci/R&D Officer | 02/01/2017 |
| CUBIST PHARMACEUTICALS INC | Chief Tech/Sci/R&D Officer | 01/01/2015 |
Formation de Lorianne K. Masuoka
| University of California, Davis | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| NEKTAR THERAPEUTICS | Health Technology |
| MARINUS PHARMACEUTICALS, INC. | Health Technology |
| DIAMEDICA THERAPEUTICS INC. | Health Technology |
| INVIVO THERAPEUTICS HOLDINGS CORP. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Health Technology |
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
| Bayer Schering Pharma AG | Health Technology |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
Opiant Pharmaceuticals, Inc.
 Opiant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Richmond, VA. | Health Technology |
Pelican Inc
 Pelican Inc BiotechnologyHealth Technology Pfenex, Inc. is a development and licensing Biotechnology Company, which focuses on leveraging its Pfenex Expression Technology platform for developing and improving protein therapies. Its products include PF708, PF743, PF745, CRM197, PF810, PF753 and PFXX. The company was founded on November 19, 2009 and is headquartered in San Diego, CA. | Health Technology |
| Berlex Laboratories, Inc. |
